Inxmed (Shanghai) Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-11-10
- Employees
- -
- Market Cap
- -
- Website
- http://www.inxmed.com
Clinical Trials
11
Active:1
Completed:2
Trial Phases
3 Phases
Phase 1:9
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (81.8%)Not Applicable
1 (9.1%)Phase 2
1 (9.1%)A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Not Applicable
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: IN10018 in combination with D-1553Drug: anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT07174908
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06166836
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳First Affiliated Hospital of Bengbu Medical College, Bengbu, China
🇨🇳Hunan Cancer Hospital, Changsha, China
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1
Recruiting
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06030258
- Locations
- 🇨🇳
Shandong Province Cancer Hospital, Jinan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, China
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Phase 2
Recruiting
- Conditions
- Ovarian Cancer Recurrent
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06014528
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT05994131
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
- Prev
- 1
- 2
- 3
- Next
News
No news found